This story first appeared at Marijuana Business Daily International. United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the... GW Pharma expects fiscal 2020 sales to reach $526 million

This story first appeared at Marijuana Business Daily International.

United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the year ended Dec. 31, 2020, it said in a preview of its fourth quarter and full-year results.

Fourth-quarter net sales will be approximately $148 million, based on preliminary unaudited financial information, GW said in a news release this week.

Epidiolex, its most successful product, accounts for most of the revenue.

Sales of Epidiolex are expected to be around $144 million for the quarter, comprising $129 million in the United States and $15 million outside the U.S.

The company said total sales of Epidiolex for the fiscal year are expected to be approximately $510 million, 41% more than in 2019.

Cash and cash equivalents as of Dec. 31, 2020 were approximately $486 million.

GW expects to report its fourth quarter and full-year results in mid-February.

The company’s shares trade on the Nasdaq as GWPH.

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

No comments so far.

Be first to leave comment below.




( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )